NVS:BCBA
Novartis CEDEAR
10 800,00 ARS
0,00%
(0,00) 1 p
19. apr, 16:40:36 GMT −3 · ARS
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse NVS põhistatistika genereerimine…
Turu kapit.
297,38 mld
Maht
0,00
Käibivad aktsiad
2,03 mld
Töötajate arv
75 tuh
Uudised
Erinevatest veebiallikatest
TradingView
·
1 päeva eest
Novartis AG expected to post earnings of $2.00 a share - Earnings Preview
Yahoo Finance
·
1 päeva eest
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Endpoints News
·
2 päeva eest
Novartis built a big business around delivering radioactive cancer treatments. Can a generic compete?
Profiil
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Teave üksuse Novartis CEDEAR kohta
TegevjuhtVasant Narasimhan
Töötajad75,3 tuh
Asutatud29. veebr 1996
PeakontoridBasel, Basel, Šveits
Sektor-
Veebisaitnovartis.com
AI genereeritud sisu võib sisaldada vigu. Lisateave